Journal Watch · British Journal of Pharmacology · 2026

State-dependent regulation of the K<sub>v</sub>7.2 channel voltage sensor by QO-58.

We anticipate that further investigation of VSD-targeted drugs will continue to clarify the complex pharmacophore of the VSD binding pocket in K<sub>V</sub>7 channels.

Kanyo R, Lamothe SM, Hammond TM, Kurata HTBritish Journal of Pharmacology3 min readPharma relevance 50/100

DOI: 10.1111/bph.70186PMID: 40937839Study type: research study

TL;DR

We anticipate that further investigation of VSD-targeted drugs will continue to clarify the complex pharmacophore of the VSD binding pocket in K<sub>V</sub>7 channels.

Key findings

  • However, K<sub>V</sub>7.2[F168W] reduces QO-58 effects, while preserving sensitivity to ICA-069673.
  • This finding indicates subtle differences in the interaction of these drugs with the VSD binding site.<h4>Conclusions and implications</h4>Key contacts underlying sensitivity to VSD-targeted potentiators may vary significantly depending on the chemical and steric features of the drug.
  • We anticipate that further investigation of VSD-targeted drugs will continue to clarify the complex pharmacophore of the VSD binding pocket in K<sub>V</sub>7 channels.

What they did

These include subtype specificity for K<sub>V</sub>7.2 over K<sub>V</sub>7.3, prominent state-dependent actions, and marked deceleration of closure of K<sub>V</sub>7.2. VSD mutations influence the actions of QO-58 and another VSD-targeted drug, ICA-069673. Interestingly, K<sub>V</sub>7.2[F168L] mutation, previously shown to abolish ICA-069673 sensitivity, does not weaken QO-58 actions.

Full abstract (original)

Background: <h4>Background and purpose</h4>K<sub>V</sub>7(KCNQ) potassium channels are key modulators of neuronal excitability, and promising targets for development of drugs for epilepsy and pain. We investigated a candidate K<sub>V</sub>7 drug, QO-58, which has been previously described but has an unclear mechanism of action.<h4>Experimental approach</h4>Targeted mutations or chimeric rearrangements of K<sub>V</sub>7 channels were used to investigate potential sites of drug binding. K<sub>V</sub>7 channels were expressed in Xenopus oocytes or HEK cells for electrophysiology and pharmacological characterisation.<h4>Key results</h4>QO-58 shares characteristic features of other voltage sensor domain (VSD)-targeted potentiators.

What they did: These include subtype specificity for K<sub>V</sub>7.2 over K<sub>V</sub>7.3, prominent state-dependent actions, and marked deceleration of closure of K<sub>V</sub>7.2. VSD mutations influence the actions of QO-58 and another VSD-targeted drug, ICA-069673. Interestingly, K<sub>V</sub>7.2[F168L] mutation, previously shown to abolish ICA-069673 sensitivity, does not weaken QO-58 actions.

Results & conclusions: However, K<sub>V</sub>7.2[F168W] reduces QO-58 effects, while preserving sensitivity to ICA-069673. This finding indicates subtle differences in the interaction of these drugs with the VSD binding site.<h4>Conclusions and implications</h4>Key contacts underlying sensitivity to VSD-targeted potentiators may vary significantly depending on the chemical and steric features of the drug. We anticipate that further investigation of VSD-targeted drugs will continue to clarify the complex pharmacophore of the VSD binding pocket in K<sub>V</sub>7 channels.

Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70186 · PubMed 40937839.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this British Journal of Pharmacology study find?

We anticipate that further investigation of VSD-targeted drugs will continue to clarify the complex pharmacophore of the VSD binding pocket in K<sub>V</sub>7 channels.

What type of study is this?

It is a research study, published in British Journal of Pharmacology in 2026. These include subtype specificity for K<sub>V</sub>7.2 over K<sub>V</sub>7.3, prominent state-dependent actions, and marked deceleration of closure of K<sub>V</sub>7.2.

Where can I read the original paper?

The original is at the publisher via DOI 10.1111/bph.70186. PubMed ID: 40937839. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Kanyo R, Lamothe SM, Hammond TM, Kurata HT. State-dependent regulation of the K&lt;sub&gt;v&lt;/sub&gt;7.2 channel voltage sensor by QO-58.. British Journal of Pharmacology (2026). DOI: 10.1111/bph.70186.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/state-dependent-regulation-of-the-k-lt-sub-gt-v-lt-sub-gt-7-2-channel-vo-h70186/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides